Vertex announces fda clearance of investigational new drug application for vx-264, a novel encapsulated cell therapy for the treatment of type 1 diabetes

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that the u.s. food and drug administration (fda) has cleared the investigational new drug application (ind) for vx-264, a stem cell-derived, fully differentiated pancreatic islet cell therapy encapsulated into a vertex-developed, immunoprotective device with the potential to treat type 1 diabetes (t1d).
VRTX Ratings Summary
VRTX Quant Ranking